Affimed N.V. | Mutual Funds
Mutual Funds that own Affimed N.V.
1,405,324
2.25%
0
1.11%
03/31/2018
362,424
0.57%
-86,276
0.45%
05/31/2018
DFA US Small Cap Portfolio
89,567
0.14%
45,004
0%
04/30/2018
DFA US Core Equity 2 Portfolio
86,693
0.14%
0
0%
04/30/2018
Fidelity Nasdaq Composite Index
51,220
0.08%
0
0%
07/31/2018
SG Actions Monde Techno
50,600
0.08%
0
0.28%
01/31/2018
DFA US Core Equity 1 Portfolio
28,571
0.05%
0
0%
04/30/2018
23,987
0.04%
23,987
0.76%
06/30/2017
Barclays MM Fd. Plc - GlobalAccess US Small & Mid Cap Equity
13,288
0.02%
0
0.03%
11/30/2017
DFA US Micro Cap Portfolio
9,800
0.02%
0
0%
04/30/2018
| Address |
Technologiepark
Heidelberg Baden Wuerttemberg 69120
Germany
|
|
Employees
|
- |
| Website |
http://www.affimed.com |
| Updated |
07/08/2019 |
| Affimed NV is a clinical stage biopharmaceutical company, which engages in discovering and developing highly targeted cancer immunotherapies. The company has three proprietary platform technologies which includes: NK-cell TandAbs, T-cell TandAbs and Trispecific Abs. The company was founded in 2000 and is headquartered in Heidelberg, Germany. |
